Transfusion-associated transmission of human T-lymphotropic virus types I and II: experience of a regional blood center.
Transfusion-associated transmission of human T-lymphotropic virus types I and II: experience of a regional blood center.
复制标题
人类 T 淋巴细胞病毒 I 型和 II 型的输血相关传播：区域血液中心的经验。
DOI：
10.1046/j.1537-2995.1993.33393174445.x
复制
发表时间：
1993
期刊：
影响因子：
2.9
通讯作者：
Lee,H
中科院分区：
文献类型：
--
作者：
Herr,V;Ambruso,D;Fairfax,M;Neumann,A;Swanson,P;Lee,H
在22个月期间，在贝儿邦菲尔斯纪念血液中心（丹佛，科罗拉多）对78，000名献血者进行了人嗜T淋巴细胞病毒I型和II型（HTLV-I/II）筛查。对阳性献血者和既往捐献血液成分的活体受者进行了与HTLV-I感染相关的风险因素和症状评估，通过酶免疫测定进行了筛查，通过Western blot确认了HTLV-I/II，随后通过聚合酶链反应和肽酶免疫测定进行了检测，以区分HTLV-I和-II感染。确定了6名血清阳性献血者（0.008%）; 4名被分型为HTLV-I感染，2名被分型为HTLV-II感染。在18名来自血清阳性供体的组分的活体接受者中，在输血前没有HTLV-I感染的风险因素，并且在随访时没有HTLV-I感染的体征或症状。从输血到检测的平均时间为6.4年。7名HTLV-I感染组分的接受者为HTLV血清阳性;所有人均被分型为HTLV-I。在1例患者中确定了一例可能的输血后HTLV‐I相关脊髓病病例，该患者在完成评价前死亡。确定了1例可能的输血相关HTLV-II病例。这些数据进一步支持继续对献血者进行HTLV-I/II筛查。
During a 22‐month period, 78,000 blood donors were screened for human T‐ lymphotropic virus types I and II (HTLV‐I/II) at Belle Bonfils Memorial Blood Center (Denver, Colorado). Positive donors and the living recipients of their previously donated blood components were evaluated for risk factors and symptoms related to HTLV‐I infection, were screened by enzyme immunoassay, confirmed by Western blot for HTLV‐ I/II, and subsequently tested by polymerase chain reaction and peptide enzyme immunoassay to distinguish between HTLV‐I and ‐II infection. Six seropositive blood donors (0.008%) were identified; four were typed as having HTLV‐I infection and two as having HTLV‐II. Of 18 living recipients of components from seropositive donors, none had risk factors for HTLV‐I infection prior to transfusion and none had signs or symptoms of HTLV‐I infection at follow‐up. The mean time from transfusion to testing was 6.4 years. Seven recipients of HTLV‐I‐ infected components were HTLV seropositive; all were typed as having HTLV‐I. A possible case of posttransfusion HTLV‐I‐associated myelopathy was identified in one patient who died before complete evaluation. One possible case of transfusion‐associated HTLV‐II was identified. These data further support the continued screening of blood donors for HTLV‐ I/II.